Aldeyra expands RASP platform to CNS diseases; reproxalap manufacturing inspections closed

Aldeyra Therapeutics, Inc.

ADX-248 preclinical results in Parkinson's & ALS models showed improved grip strength, balance, and CNS biomarkers.
FDA completed reproxalap drug substance and product facility inspections; closed with VAI designation, no further action.
Aldeyra expanded RASP platform to central nervous system diseases; ADX-248 is oral next-gen RASP modulator.
Reproxalap is a first-in-class investigational candidate for dry eye disease signs and symptoms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.